The Ypsomed mylife YpsoPump combines with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3. Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can better control glucose levels and alleviate the burden of daily diabetes management.
Mylife Loop offers an intelligent, automated process for insulin dosing, according to a news release. It does so based on real-time glucose data from the Abbott FreeStyle Libre continuous glucose monitor (CGM). CGM data allows for the administration of the appropriate amount of insulin at the right time.
Abbott, Ypsomed and CamDiab announced a partnership to develop an AID earlier this year. They seek to develop and commercialize the integrated AID system with an initial focus in European countries.
Providing options for those with diabetes
Ypsomed already launched mylife Loop in partnership with CamDiab this past summer in a number of countries. Enabling the Abbott FreeStyle Libre 3 CGM to work with the platform gives type 1 diabetes patients options. They can choose between the Dexcom G6 and Abbott FreeStyle Libre 3 and they can customize their loop.
“We are convinced that the major challenges facing society can only be solved through partnerships. We are therefore proud to expand our offering with Abbott to give the users of our mylife YpsoPump more freedom of choice in managing their diabetes,” said Sébastien Delarive, chief business officer, diabetes care, Ypsomed. “Our compact and easy-to-use insulin pump authorized to work with Abbott’s latest sensor and CamDiab’s adaptive hybrid closed-loop app will change the lives of thousands of people affected by diabetes.”
Abbott, CamDiab and Ypsomed offer the integrated AID system in Germany for now. They plan for other European countries to follow. It currently has availability for Android and the companies expect iOS to follow in the second half of 2023.